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https://doi.org/10.1016/j.stemcr.2018.11.011Cardiovascular disease is still a major cause of ill-health and
mortality, heart failure and arrhythmia being among the causes
of sudden cardiac death. There are few drugs available for treat-
ment or prevention and it remains difficult to predict who will
develop these conditions, even when disease-causing mutations
or associated gene variants are identified in individuals or
families. This is in part because widely used rodent models
may not fully capture the physiology of the human heart. The
advent of pluripotent stem cell technology that allows cardio-
vascular cells to be derived from patients and healthy individ-
uals, in some cases genetically matched through mutation
repair, is leading to paradigm shifts in how cardiovascular
diseases are studied in humans. However, these cells are often
only partially mature imposing some limitations in use. This
Perspective reviews aspects of recent advances but also remain-
ing challenges.Introduction
The ability to generate induced pluripotent stem cells
(iPSCs) by reprogramming somatic tissues is arguably the
greatest breakthrough in biomedical science of the last
decade. It means that the most inaccessible cells of the
body, such as those of the heart, can now be derived repeat-
edly from any individual without the ethical limitations of
embryonic stem cells (ESCs). While first excitement con-
cerned the potential for allogenic transplantation in regen-
erative medicine, focus has now shifted to more medically
relevant areas: (cardiac) disease modeling, target discovery,
and drug development. These applications, however, are
requiring new levels of sophistication in bioassays to
monitor disease phenotypes so that the predictive value
of hiPSCs can be realized for acute and chronic genetic
and somatic diseases. In addition, generating cell subtypes
in the heart benefits from detailed knowledge of the devel-
opmental pathways that lead to the formation of these cells
in the embryo (reviewed in Birket andMummery, 2015). As
these areas have merged over the last several years, they
have created unique opportunities to create new human
models of organ physiology and pathology that are leading
to greater understanding of mechanisms underlying
abnormal human development and the cause of disease.
This is now beginning to provide unprecedented opportu-
nities to identify new markers for diagnosis and molecular
targets for prevention and therapeutic intervention in
multiple disease states.1306 Stem Cell Reports j Vol. 11 j 1306–1311 j December 11, 2018 j ª 2018
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Cardiovascular disease is a major cause of morbidity and
mortality in the developed world, second only to cancer
in the number of individuals affected. In contrast to cancer,
however, there are few new drugs in the pipeline, in part
because cardiac and vascular diseases have been difficult
to model in laboratory assays or experimental animals.
Rodent hearts, for example, beat between 250 and
500 times per min, a human heart at rest only 60 times
per min. Physiology between species is therefore different,
in part due to differences in size, in part due to different
levels of ion channel proteins that mediate contractile
and electrical signals (Figure 1). Most notably, one impor-
tant K+-channel (the HERG channel) in human cardiomyo-
cytes that regulates heart rate and is the target of drugs and
gene mutations causing arrhythmias, is negligible in mice
so that abnormalities mediated by aberrant behavior of
this channel are largely undetectable. As a result of these
and other differences, heart failure, atherosclerosis, and
cardiovascular complications of diabetes, have few treat-
ment options that can be offered in the clinic despite
huge investments by the pharmaceutical industry (Paul
et al., 2010).
Since human iPSCs (hiPSCs) can divide indefinitely
and in principle form any cell of the body, heart, and
vascular cells can be generated from individuals of any
ethnic background who may be healthy or have any of
a multiplicity of diseases of genetic or unknown origin.
In addition, recent technical advances in gene targeting
using CRISPR/Cas9 technology in human PSCs (hPSCs)
mean that any mutation or gene variant of interest
can be introduced either to correct gene mutations or
introduce them on a healthy control background (Bellin
et al., 2013). In addition, rapid targeting of reporter
genes into loci of interest facilitates the lineage tracing
in culture and cell subtype selection (Schwach et al.,
2017). Thus, not only is there potential to use these
new windows of opportunity to slow disease progression
and identify factors that predetermine its degree of
severity but it may also be possible to target specific dis-
ease mechanisms and develop cures. If the symptoms in
the hiPSCs and their derivatives could be alleviated, the
same approach may be feasible directly in the patient.
If adverse drug responses were identified in specificThe Author(s).
ecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Comparison of Ion Channel Use on Human and Mouse
Cardiomyocytes
Mouse hearts are smaller, beat faster, and have different ion
channel expression profiles that human cardiomyocytes.
(A) Ion channels present on mouse and human cardiomyocytes; the
length of the arrows corresponds to the amount of current carried
by the channel (INa values are similar in mice and humans so that
mutations or drugs affecting these channels will show similar re-
sponses in both species; IKr [HERG channel] differs between species
so that mouse hearts show lower responses than humans). LQT
(long QT) refers to the syndromes associated with mutations in the
ion channels indicated.
(B) Electrocardiograms of humans and mice show corresponding
differences in shape. The middle electrocardiogram shows that of
mice on the same scale as human.
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clinical disaster. Side effects of drugs are now among the
leading causes of death worldwide and many of these
effects are due to cardiotoxicity.
hiPSCs can now differentiate efficiently into cardio-
myocytes and vascular cells (reviewed in Mummery
et al., 2012) and there are numerous examples of how
this approach has led to important insights in cardiac dis-
ease mechanisms (Bellin et al., 2013; Wang et al., 2014).
This is despite the widely reported immaturity of differen-
tiated derivatives of hiPSCs, including cardiomyocytes
(reviewed in Veerman et al., 2015). It is now feasible to
obtain certain types of cardiac and vascular cells that cap-
ture entire genetic profiles, not only of mutated genes
(when the gene is known) but also all the genetic modi-
fiers that play an important but yet largely unknown
role in the pathology of cardiovascular disease and drug
responses.
The concept of differentiated hiPSCs and (mutated)
hESCs as ‘‘patients’’ has started receiving robust support
in experimental data: reprogrammed cells from patients
with rare genetic disorders are already experimental
paradigms that are providing new clues on how diseases
cause damage and how this might be alleviated or
reversed.Lessons from Development: Directing Cardiovascular
Differentiation of hPSCs
In vitro differentiation of stem cells to cardiomyocytes and
vascular cells mimics the sequential stages of embryonic
cardiac development (for review see Birket and Mummery,
2015). The heart and associated vessels are the first identifi-
able tissues to develop in vertebrate embryos. The heart
forms soon after gastrulation from anterior migrating
mesodermal cells that intercalate between the ectoderm
and endoderm cell layers in the primitive streak. The first
vessels appear on the yolk sac enveloping the embryo.
Multipotent cardiac progenitor cells are primarily localized
in the mid-streak where signals from the adjacent endo-
derm, in particular, appear to have a highly conserved
instructive function in cardiogenesis. Two families of pro-
tein growth factors are thought to control these early stages
of mesoderm formation and cardiogenesis: nodal and bone
morphogenetic proteins (BMPs), which aremembers of the
transforming growth factor b superfamily, and the Wnt
proteins. These factors, or their inhibitors, are expressed
in the endoderm; genetic disruption of their signaling
has dramatic effects on cardiac development. In verte-
brates, BMP signaling generally promotes cardiogenesis,
while Wnt proteins are involved in cardiac specification.
Differentiation of mesoderm to vascular cells requires
different signaling pathways, the most important being
that induced by vascular endothelial growth factor (Carme-
liet, 2003). Overall, it appears that the timing and relative
expression of different growth factor combinations induce,
then pattern, the cardiogenic mesoderm. Once mesoderm
cells have received appropriate signals, they switch on a
highly conserved heart-specific combination of transcrip-
tion factors that establish the cardiac transcriptional
program. Initially, the mesodermal precursor cells in the
primitive streak express transcription factors such as
the T-box factor Brachyury (T) and the homeodomain pro-
tein, Mixl1. Prior to migration from the streak, these cells
transiently activate the basic helix-loop-helix transcription
factor mesoderm posterior 1 (Mesp1) to enter a ‘‘precar-
diac’’ mesoderm stage of development. A subset of the
Mesp1+ cell population then begins to express the homeo-
domain transcription factor Nkx2-5, the T-box protein
Tbx5, and Isl1, a LIM homeodomain transcription factor,
which are early markers of the cardiac lineage that are acti-
vated shortly after the formation of the heart fields. In
mice, Nkx2-5 is essential for the interpretation of
patterning signals within the primitive heart tube and is
likely to act in concert with Tbx5 during formation of
both the atrial and left ventricular compartments to posi-
tively regulate transcription. Nkx2-5 and Tbx5 associate
with members of the GATA family of zinc-finger transcrip-
tion factors and with serum response factor to activate
cardiac structural genes, such as actin, myosin light chain,Stem Cell Reports j Vol. 11 j 1306–1311 j December 11, 2018 1307
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cooperate with Nkx2-5 to activate expression of ANF and
the junctional protein connexin 40. Members of the myo-
cyte enhancer factor 2 family of transcription factors also
play key roles in cardiomyocte differentiation by regulating
cardiacmuscle structural genes. Thus,multiple complex in-
teractions between this highly conserved gene-regulatory
networks control the initial differentiation, proliferation,
and maturation of cardiomyocytes. Apart from their func-
tional role, many of these factors can be used as markers
of emerging cardiomyocytes in differentiating cultures of
hPSCs. In rather a similar way, a set of markers that may
also be functional proteins have been described for endo-
thelial cells and vascular smooth muscle cells. These
include the vascular endothelial growth factor receptors,
a-smooth muscle actin and platelet endothelial cell adhe-
sion molecule.
hiPSC Lines Modeling Cardiac Disease
hiPSC lines have been created frommany individuals with
cardiac disease, predominantly with mutations in ion
channel genes (reviewed in Branda˜o et al., 2017) or in sar-
comeric proteins (reviewed in Giacomelli et al., 2017b).
For the ion channel mutations that lead to arrhythmias
and sometimes sudden cardiac death (SCD), hiPSC-
derived cardiomyocytes have not only been shown to
recapitulate the disease phenotypes but, as mentioned
earlier, have also provided new insights into underlying
disease mechanisms or have indicated treatment modal-
ities. These ion channelopathies are of particular interest
because ion channel use is different in the smaller hearts
of rodents so that relevant animal models are unavailable.
For example, mouse models with mutations in Kcnq1 are
available but there are significant differences in the
handling of rectifying potassium currents between mouse
and human (Davis et al., 2011). Since cardiac ion channels
are expressed within 2 weeks of initiating cardiomyogenic
differentiation in hPSCs, cardiomyocyte immaturity has
had a relatively little impact on predictive outcomes for
adult humans. For this reason, hPSC models have to
some extent surpassed mice as useful for determining
drug sensitivities, since many of these channelopathies
are autonomous to the cardiomyocytes (Blinova et al.,
2018; Braam et al., 2013).
Changes in electrical properties of hPSC-cardiomyocytes
as a result of disease or in response to drugs can be deter-
mined relatively reliably using electrophysiology (patch
clamp with microelectrodes or microelectrode arrays) or
optical methods using voltage- and calcium-sensitive
dyes (reviewed in van Meer et al., 2016). By contrast, phe-
notypes resulting from cardiac hypertrophy or myopathy
have been more difficult to capture since until recently
there have been few satisfactory ways to measure the alter-1308 Stem Cell Reports j Vol. 11 j 1306–1311 j December 11, 2018ations in cardiomyocyte size or contractility evident in
patients.
The first report of hiPSC-cardiomyocytes from a patient
with hypertrophic cardiomyopathy concerned LEOPARD
syndrome. Patients with this condition suffer from various
symptoms, with hypertrophic cardiomyopathy the cause
of mortality in some sufferers. This autosomal-dominant
hereditary disorder is commonly caused by mutations in
the tyrosine phosphatase gene, PTPN11, which is ubiqui-
tously expressed throughout the body and is essential
for normal development. hiPSCs, generated from two pa-
tients with one of the most recurrent mutations, T468M,
were differentiated to cardiomyocytes, and assessed for hy-
pertrophy (Carvajal-Vergara et al., 2010). The hiPSC-
cardiomyocytes displayed a higher degree of sarcomeric
organization and nuclear NFATC4 localization and were
larger than wild-type hiPSC-cardiomyocytes, which are
highly disorganized and immature. However, not all stan-
dard criteria to analyze cardiomyocyte hypertrophy could
be performed due to themixed population of cells obtained
from the differentiation procedure and the interpretation
of increased cardiomyocyte spreading as increased size
is perhaps in retrospect somewhat over interpreted.
Nevertheless, this type of study set the stage for many
more robust myopathy models and there is now much
greater insight into these conditions as a result of improved
differentiation strategies to enrich for cardiomyocytes
and better functional assays that reflect disease phenotypes
in patients.
Cell-Based Screening for Drug Discovery
Although hiPSC technology could be instrumental in un-
derstanding the biology of healthy and diseased cardio-
myocytes, this might not be enough for efficient drug
target identification. Over the last two decades, several
gene mutations causing cardiac disease have been identi-
fied through candidate gene approaches in families exhib-
iting hereditary cardiac abnormalities, but it has proven
extremely difficult to translate this to the identification of
drug targets and therapies.
Cell-based screening with a phenotypic endpoint is
now proving to be a successful solution to this in some dis-
ease areas. Typically, primary human cells are used to
create in vitro disease models in culture with a finite ‘‘win-
dow for screening.’’ Thesemodels can be used in combina-
tion with either RNAi technology to find drug targets, or
chemical libraries to find novel lead molecules. As previ-
ously mentioned, primary human cardiomyocytes are
difficult to obtain and cannot be maintained in culture
for longer than a few days, making them unsuitable for
high throughput screening. Using hPSCs and differen-
tiation protocols that generate high yields of cardiomyo-
cytes might solve this problem. hPSC disease models
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developed into miniaturized high-throughput and high-
content phenotypic screening assays. A range of assays
to identify a response are available and can be based on
fluorescent imaging, immunochemistry, and/or multi-
plexing (van Meer et al., 2016). This allows for a complex
assay design, based on simultaneous measurements of
parameters such as cell proliferation, differentiation,
morphology, and viability and will be the approach taken
in the present proposal.
Personalized Medicine and Stem Cell Banks
The late-stage attrition of drugs due to limited effectiveness
or to unforeseen side effects is perhaps the biggest problem/
risk in drug development. To some extent, this is because
not all individuals receiving a drug for a specific symptom
will have a beneficial response or suffer a toxic side effect.
A panel of PSC lines with different genotypes and from
different racial backgrounds will allow in vitro analyses, pre-
dicting both drug effectiveness and toxicity at an individ-
ual level against a specific genetic background, as well as
identifying biomarkers for the development of companion
diagnostic assays to predict individual therapy response
and toxicity in the clinic.
The potential clinical implications of personalized
hiPSC-cardiomyocytes and how they might be imple-
mented to guide clinical decisions was recently illustrated
by a study in which genome editing was combined with
hiPSCs from an asymptomatic patient carrying a hypertro-
phic cardiomyopathy genetic variant in the sarcomeric
protein MYL3 (Ma et al., 2018). This variant has been clas-
sified as ‘‘likely pathogenic,’’ creating a clinical dilemma on
whether to place an intra cardiac device (ICD) into a pa-
tient without symptoms in case an arrhythmic event
should take place. ICDs may activate spontaneously in
the absence of arrhythmia, causing significant patient
stress. Clinical genetic testing is emerging as the standard
of care in patients but interpretation of clinical risk is often
confounded by ‘‘variants of unknown significance’’ (VUS).
VUS patient hiPSC-cardiomyocytes derived from the het-
erozygous carrier underwent targeting of the second
(healthy) allele either with the VUS or a frameshift muta-
tion in the same gene to create homozygous isogenic pairs.
The heterozygous VUS-hiPSC-cardiomyocytes did not
show the hypertrophic cardiomyopathy phenotype, but,
more importantly, neither did the gene-edited homozy-
gous lines, supporting a benign assessment of this partic-
ular MYL3 variant. This hiPSC-based assay is now being
used to indicate which patients would be at risk of SCD
and would benefit from placement of an ICD. This is in
linewith earlier studies showing that any drugs or gene var-
iants that compromise repolarization reserve present an
additional risk (Braam et al., 2013).Challenges for the Field
Whilemany laboratories worldwide are developing human
iPSC disease models, and the overall disease phenotype of
the patient is apparently retained in these cells, there are
at least two general questions still to be answered. Firstly,
what canwe learn about the disease that cannot be gleaned
from studying the patients. For example, in many electro-
physiological disorders, the physiological basis for the
arrhythmia is already known. While there is emerging evi-
dence that hiPSC models for genetic ion channelopathies
can help us further understand the molecular mechanism
behind the disease and develop new therapeutic interven-
tions (e.g., Braam et al., 2013; Zhang et al., 2014), it is not
yet clear how closely the in vitro disease phenotype will
match that of the patient from whom they were derived,
particularly in terms of severity. In some familial hypertro-
phic cardiomyopathies, one example described a boy in
which the cardiac septum was 10 times thicker than
normal, yet his father with the same mutation has no
apparent symptoms (Birket et al., 2015). It remains to be
seen whether such obvious differences in the sensitivity
of the patient’s cardiomyocytes to undergo hypertrophy
will be similarly reflected in the cardiomyocytes derived
from their respective iPSC lines.
A potential technical issue mentioned earlier is that
in-vitro-differentiated derivatives of hPSCs typically have
an immature phenotype. For hPSC-cardiomyocytes this
means that their gene expression profile resembles that of
fetal cardiomyocytes (reviewed in Veerman et al., 2015).
In addition, their resting membrane potentials and up-
stroke velocities are small compared with adult cardiomyo-
cytes, and their sarcomeres and shapes are relatively
disorganized and not aligned as in adult cells, potentially
limiting their utility in disease modeling and drug
screening. Understanding and recapitulating in vitro the
physiological and biochemical triggers active in normal
development will be essential to achieve this goal. One
study recently reported such an approach where hPSC-
cardiomyocytes were cultured as engineered heart tissues
(EHTs) then subjected to ‘‘exercise’’ at increasing pacing
rates up to 6 Hz (Ronaldson-Bouchard et al., 2018). EHTs
are 3D heart muscle equivalents in which hPSC-cardio-
myocytes are embedded in collagen gels such that they
contract against a load provided by poles at each end of
the tissue (Ulmer et al., 2018). The paced tissues showed
many features of mature myocardium including increased
numbers of mitochondria, reflecting altered metabolism,
and t-tubules, structures evident by electron microscopy
that are essential for proper calcium handling and only
develop postnatally in humans.
It should also be noted that the heart is not only
composed of cardiomyocytes (30% of the total cells pre-
sent in the adult heart; 60% in fetal heart), but also twoStem Cell Reports j Vol. 11 j 1306–1311 j December 11, 2018 1309
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muscle cells and vascular endothelial cells. While electro-
physiological disorders and cardiomyopathies are cell-
autonomous disorders affecting solely the cardiomyocytes,
for other cardiac diseases these other cell types also play
important roles, influencing the cardiomyocytes both
in terms of their response to injury and to cardiac and
non-cardiac drugs. A stem cell-based model that recapitu-
lates cardiac organogenesis, essentially creating an artificial
human myocardium, would be invaluable.
Aside from the genetic forms of cardiac disease, there are
many cardiac conditions caused by abnormal physiological
insults. In the human heart itself, these can include lack
of oxygen during a myocardial infarction, high blood
pressure, high glucose levels due to diabetes, and changes
in cardiomyocyte shape from cardiac remodeling post
myocardial infarction or heart failure. In some cases,
these changes can be recapitulated in the laboratory
using chemicals or drugs such as phenylephrine or in the
case of shape changes, by micropatterning extracellular
matrix proteins such as fibronectin onto synthetic poly-
mers. Alternatively, cryoinjury has been used to mimic
aspects of cardiac repair in vitro in cardiac organoids (Mills
et al., 2017a, 2017b). Combined with monogenetic disease
hPSC lines, this will provide an extensive collection of
paradigms for downstream applications.
Toward Solutions: Implementing hPSCs in Disease
Pathology and Drug Discovery
Several recent studies including from our own lab (Giaco-
melli et al., 2017a) have described methods for creating
synthetic human myocardium and associated vasculature
that show the features of mature heart tissue, but which
can also show characteristics of disease. Robust methods
for producing the cellular components of the heart and
vasculature are being developed, and assembled into either
synthetic or natural structures that can be mechanically,
electrically, or biochemically challenged, and for which
readouts of function are quantifiable and reproducible.
This may contribute in the future to heart and vascular
repair, but a more immediate outcome is the creation of
authentic models of the healthy and diseased human
cardiovascular system and accompanying bioassays of
functionality that can be applied to drug safety and discov-
ery, as mentioned earlier.
New diseases are continuously being added to the list of
those that recapitulate not only genetic but also sporadic
forms of disease. This new technology thus has great poten-
tial in bringing new insights into cardiovascular develop-
ment and disease in humans far beyond the anticipated
uses in cell-replacement therapy. Patient-specific iPSCs
have rapidly emerging applications in disease modeling,
drug testing, and drug discovery since, compared with1310 Stem Cell Reports j Vol. 11 j 1306–1311 j December 11, 2018other organs, heart tissues are particularly inaccessible
as patient biopsies. Models of disease ‘‘in a dish,’’ are now
allowing experiments that, not so long ago, would
have been inconceivable. Before this potential can be
fully realized, however, there are a number of important
hurdles to overcome. These will not only require excep-
tional expertise in hPSC biology, but also exquisite knowl-
edge of the underlying developmental biology, to drive
differentiation efficiently and reproducibly to the required
cell types and multidisciplinary approaches to developing
sensitive and quantitative assays of deviant phenotypes
in ‘‘diseased’’ cells.
The impact will be to provide new paradigms for under-
standing disease mechanisms, drug safety pharmacology,
and discovering new therapeutic drugs.
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